Invasive aspergillosis in chronic granulomatous disease
Aspergillosis: From Diagnosis to Prevention, Page: 527-543
2010
- 6Citations
- 26Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Book Chapter Description
Chronic granulomatous disease (CGD) is a rare inherited disorder of the NADPH oxidase complex in which phagocytes are defective in generating superoxide anion. NADPH oxidase activation leads to release of sequestered neutrophil granular proteases, which are likely the principal antimicrobial effectors. CGD is characterized by recurrent life-threatening bacterial and fungal infections and by inflammatory complications such as wound dehiscence, obstructive granulomata of the genitourinary tract, and inflammatory bowel disease. Despite routine use of interferon-gamma prophylaxis, fungal infections have remained a persistent problem with an incidence of 0.1 fungal infections per patient year. Invasive pulmonary aspergillosis in CGD manifests with neutrophils and lymphohistiocytic inflammation; hyphal angioinvasion is not observed, indicating that NADPH oxidase-independent pathways appear to be adequate to protect against vascular invasive disease. Chronic prophylaxis with a mould-active agent is standard of care in CGD. Mulch pneumonitis is characterized by rapid onset life-pulmonary inflammation following mould exposure, and treated with systemic antifungals and prolonged corticosteroids. Haematopoietic stem cell transplantation is curative in CGD, but transplant-related mortality from GVHD and infectious complications is substantial, particularly in cases of donor/recipient HLA-antigen disparity. Since CGD is a disorder of myeloid stem cells, gene therapy is an attractive option, but maintaining stable population of myeloid gene-corrected cells has been a persistent challenge. The strategy of non-myeloablative conditioning followed by gene therapy facilitates the expansion of gene-corrected cells. Studies of experimental aspergillosis in CGD point to defective tryptophan metabolism as a contributing factor to impaired host defence and increased lung inflammation in CGD.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84919623390&origin=inward; http://dx.doi.org/10.1007/978-90-481-2408-4_31; http://link.springer.com/10.1007/978-90-481-2408-4_31; http://link.springer.com/content/pdf/10.1007/978-90-481-2408-4_31.pdf; https://doi.org/10.1007%2F978-90-481-2408-4_31; https://dx.doi.org/10.1007/978-90-481-2408-4_31; https://link.springer.com/chapter/10.1007/978-90-481-2408-4_31; http://www.springerlink.com/index/10.1007/978-90-481-2408-4_31; http://www.springerlink.com/index/pdf/10.1007/978-90-481-2408-4_31
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know